Learn key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 380 KB
Released: February 15, 2022
Acknowledgements
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
